- Home
- SOR vs CRDF Comparison
SOR vs CRDF Comparison
Compare SOR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- CRDF
- Stock Information
- Founded
- SOR 1968
- CRDF 1999
- Country
- SOR United States
- CRDF United States
- Employees
- SOR N/A
- CRDF N/A
- Industry
- SOR Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOR Finance
- CRDF Health Care
- Exchange
- SOR Nasdaq
- CRDF Nasdaq
- Market Cap
- SOR 347.3M
- CRDF 288.7M
- IPO Year
- SOR N/A
- CRDF N/A
- Fundamental
- Price
- SOR $42.45
- CRDF $4.75
- Analyst Decision
- SOR
- CRDF Strong Buy
- Analyst Count
- SOR 0
- CRDF 3
- Target Price
- SOR N/A
- CRDF $10.33
- AVG Volume (30 Days)
- SOR 16.2K
- CRDF 948.4K
- Earning Date
- SOR 01-01-0001
- CRDF 02-27-2025
- Dividend Yield
- SOR 7.24%
- CRDF N/A
- EPS Growth
- SOR N/A
- CRDF N/A
- EPS
- SOR 6.50
- CRDF N/A
- Revenue
- SOR N/A
- CRDF $688,000.00
- Revenue This Year
- SOR N/A
- CRDF $25.03
- Revenue Next Year
- SOR N/A
- CRDF N/A
- P/E Ratio
- SOR $6.41
- CRDF N/A
- Revenue Growth
- SOR N/A
- CRDF 49.57
- 52 Week Low
- SOR $36.41
- CRDF $1.65
- 52 Week High
- SOR $42.75
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- SOR 46.15
- CRDF 62.77
- Support Level
- SOR $42.29
- CRDF $4.12
- Resistance Level
- SOR $43.23
- CRDF $4.38
- Average True Range (ATR)
- SOR 0.55
- CRDF 0.38
- MACD
- SOR 0.09
- CRDF 0.04
- Stochastic Oscillator
- SOR 32.94
- CRDF 80.17
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").